Merck’s sprifermin slows cartilage loss

A proof-of-concept trial published in April in Arthritis & Rheumatology reported that intra-articular injection of 100µg sprifermin (recombinant human fibroblast growth factor 18), made by Merck Serono S.A. of Geneva, Switzerland, reduced loss of total femorotibial joint cartilage thickness and volume in the lateral knee compartment of patients with knee osteo­arthritis

A proof-of-concept trial published in April in Arthritis & Rheumatology reported that intra-articular injection of 100µg sprifermin (recombinant human fibroblast growth factor 18), made by Merck Serono S.A. of Geneva, Switzerland, reduced loss of total femorotibial joint cartilage thickness and volume in the lateral knee compartment of patients with knee osteo­arthritis

More here:
Merck’s sprifermin slows cartilage loss